View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
Rhabdomyolysis with Ezetimibe. The Medical Letter 2005;47(1203):17.
The Canadian equivalent of the Food and Drug Administration has issued a warning about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis, and thrombocytopenia detected in patients who were taking ezetimibe (Zetia). Ezetimibe is used alone or, in the United States, is marketed in a combination with simvastatin (Vytorin). There have been previous case reports of myalgia that have occurred when ezetimibe was added to a previously tolerated statin. These new Canadian reports should alert patients and clinicians that rhabdomyolysis is a potential risk associated with the use of ezetimibe even though it was not detected in initial trials.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top